AdjuTec Pharma AS

AdjuTec Pharma is Awarded NOK 16mill to Support Clinical Trials

Oslo, Norway, 15 December 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. Today the Company received a positive response from the Norwegian Research Council (NRC), offering NOK 16 mill to take our lead product APC148 through early-stage clinical testing.

Adjutec will apply for starting a first-in-man study with our lead product APC148 alone early 2024. This study will give important safety data and is the first of several phase 1 studies to investigate the antibiotic and enzyme inhibitor (APC148) doses to be combined. The grant will support these clinical trials as well as further microbiology testing of multi-resistant bacteria and in-vivo safety testing.

“This award is fantastic news that will secure fast-track development of our lead product APC148. APC148 combined with antibiotics, restores efficacy against multidrug resistant bacteria. Obtaining clinical phase 1 safety data will take the company to an important inflexion point, making the project attractive to international pharma. The grant is a great external evaluation of the science and medical need for our novel antibiotic product”, comments Bjørn Klem, CEO of AdjuTec Pharma.

About antimicrobial resistance (AMR) –

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit

Please contact:

Follow us on LinkedIn and Twitter